Randall Chin

Dr. Randall Chin is the Director of Biomarkers at Mitokinin. He and his team are focused on developing patient selection, target engagement, and pharmacodynamic biomarkers for Mitokinin’s PINK1 program. As one of the first employees of Mitokinin, Dr. Chin previously led the development of the Company’s small molecule screening cascade.

Before Mitokinin, Dr. Chin worked at Alexion Pharmaceuticals, designing mRNA-based therapies for mitochondrial disease. Dr. Chin has published papers in Nature, PNAS, and Cell Reports, and holds several patents. He received his PhD in Molecular Biology from UCLA, where he studied the molecular mechanisms of aging in model organisms.